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The role of dendritic cells (DCs) in directing the immune response is due in part to their
capacity to produce a range of cytokines. Importantly, DCs are a source of cytokines, which
can promote T cell survival and T helper cell differentiation. While it has become evident
that soluble-N-ethylmaleimide-sensitive-factor accessory-protein receptors (SNAREs) are
involved in membrane fusion and ultimately cytokine release, little is known about which
members of this family facilitate the secretion of specific cytokines from DCs. We profiled
mRNA of 18 SNARE proteins in DCs in response to activation with a panel of threeToll-like
receptors (TLR) ligands and show differential expression of SNAREs in response to their
stimulus and subsequent secretion patterns. Of interest, STX3 mRNA was up-regulated in
response to TLR4 and TLR7 activation but not TLR2 activation. This correlated with secre-
tion of IL-6 and MIP-1α. Abolishment of STX3 from DCs by RNAi resulted in the attenuation
of IL-6 levels and to some extent MIP-1α levels. Analysis of subcellular location of STX3
by confocal microscopy showed translocation of STX3 to the cell membrane only in DCs
secreting IL-6 or MIP-1α, indicating a role for STX3 in trafficking of these immune mediators.
Given the role of IL-6 in Th17 differentiation, these findings suggest the potential of STX3
as therapeutic target in inflammatory disease.
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INTRODUCTION
Since the discovery of soluble-N-ethylmaleimide-sensitive-factor
accessory-protein receptors (SNAREs) in the 1980s they have been
defined to have an essential role for the trafficking of molecules
and membranes within cells (1). To date, there are 38 members
of the SNARE family and the subcellular locations and differential
combinations of SNARE proteins differ between cell types. The
pairing of SNARE proteins is selective, which limits trafficking
and membrane fusion between intracellular organelles or mem-
brane fusion (2). Studies investigating the expression of individual
SNAREs and their subcellular locations have led to the mapping of
intracellular pathways. More advanced work has begun to assign
functions to SNAREs in specific cellular immune responses such as
the role of STX6 and Vti1b in the secretion of TNF from activated
macrophage (3).
Dendritic cells are essential for the generation of a func-
tional immune response. They do so by the capture and process-
ing of antigens, expression of surface co-stimulatory molecules,
migration to lymphoid organs, and secretion of cytokines and
chemokines (4). Understanding these actions, such as their ability
to drive T helper cell responses makes the dendritic cells (DC) a
powerful tool for manipulating the immune system. Furthermore,
the cytokines they secrete are associated with the pathogenesis of
a wide range of inflammatory diseases (5). For example, blockade
of TNF-α has been clinically successful in a number of immune
mediated pathologies such as rheumatoid arthritis, Crohn’s dis-
ease, and psoriasis (6). Abolishment of IL-23 by either utilizing
IL-23 knockout mouse models or subjecting wild-type mice to
anti-IL-23 treatment has been shown to render mice resistant to
certain inflammatory and autoimmune diseases such as experi-
mental autoimmune encephalitis (EAE), collagen-induced arthri-
tis (CIA), and inflammatory bowel disease (IBD) (7–9). As DCs
act as a link between innate and adaptive immunity and secrete
cytokines, which are important in inflammatory diseases, investi-
gating how DCs secrete these cytokines may provide us with new
therapeutic targets in these diseases.
To date, there has been little work exploring the expression or
function of SNAREs in DCs. The most notable studies include
a profile of SNARE expression in DCs of Vti1a, Vti1b, VAMP3,
VAMP8 and STX8, which were up-regulated in response to acetyl-
salicylic acid (ASA) (10). Furthermore, Ho et al., in 2008 attributed
a functional role to VAMP8 in DCs. They demonstrated that over-
expression of VAMP8 resulted in significant inhibition of phagocy-
tosis and VAMP8−/− DCs had significantly increased phagocytic
ability indicating that VAMP8 could inhibit phagocytosis from
DCs (11).
To investigate the role of SNAREs in DC secretion we profiled
the expression of mRNA following activation with a panel of Toll-
like receptors (TLR) ligands using the established JAWS II DC cell
line. We hypothesized that an up-regulation of particular SNAREs
in DCs following activation may be indicative of a role for them
in the secretion of cytokines or chemokines. This is the first study
to demonstrate that activation of DCs with TLR ligands results
in the differential expression of SNARE proteins, which correlates
with the profile of cytokines and chemokines being secreted by the
cell. Furthermore, we confirmed a role for STX3 in the secretion
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of IL-6 using RNAi. This study suggests that SNARE proteins may
provide new therapeutic targets in inflammatory disease.
MATERIALS AND METHODS
ANIMALS AND MATERIALS
C57BL/6 mice were purchased from Charles River at 6–8 weeks of
age. Animals were housed in a licensed BioResource Unit (Dublin
City University), according to Health Products Regulatory Author-
ity (HPRA) regulations and had ad libitum access to animal chow
and water. LPS E. coli serotype R515 was purchased from Enzo Life
Sciences. Loxoribine and PGN from InvivoGen, rGMCSF from
Sigma Aldrich, and STX3 siRNA from Life Technologies.
DENDRITIC CELL CULTURE
A murine DC line JAWS II (CRL-11904) was purchased from
ATCC and maintained in fully supplemented α-MEM supple-
mented with 10% (v/v) fetal bovine serum (FBS), 2% (v/v)
Penicillin–Streptomycin, and 5 ng/ml rGM-CSF. Bone marrow
dendritic cells (BMDCs) were harvested from the femurs and tibia
of mice and were also cultured in fully supplemented α-MEM. On
day three, supernatants were removed from BMDCs and replaced
with fresh fully supplementedα-MEM. On day seven BMDCs were
used for subsequent experiments.
QUANTITATIVE POLYMERASE CHAIN REACTION
JAWS II DCs were cultured for 7 days in the presence of murine
recombinant GM-CSF (Sigma Aldrich) and plated at 1× 106
cell/ml. Cells were then stimulated with 5µg/ml PGN, 100 ng/ml
LPS (E. coli serotype R515), or 1 mM Loxoribine over a time-
course. Total RNA was extracted, converted to cDNA, which was
then subjected to quantitative real-time PCR. 2−∆∆Cq formula of
the delta–delta Cq method was used and a fold change in expres-
sion of SNARE genes was normalized against that of endogenous
control S18. SNARE mRNA levels were determined relative to
expression in the absence of TLR stimulation, which is given an
arbitrary value of 1. All primer sequences are listed in Table 1.
DC STIMULATION AND MEASUREMENT OF CYTOKINES AND
CHEMOKINES
JAWS II DCs or BMDCs were stimulated with LPS (100 ng/ml),
Loxoribine (1 mM) or PGN (5µg/ml) at timepoints between 0
and 12 h. Culture supernatants were removed and stored at−80°C
until further analysis. IL-1β, IL-6, TNFα, MIP-1α concentrations
in cell culture supernatants were analyzed by DuoSet ELISA Kits
(R&D Systems) according to manufacturer’s instructions.
RNAi OF STX3
JAWS II DCs were plated and left to rest overnight. GeneSilencer®
(Genelantis) reagent and serum free media were added to tube
one. siRNA diluent, specific STX3 siRNAs (Invitrogen™) (1 nM)
(Table 2) or 1 nM scrambled non-silencing siRNA or 1 nM of
fluorescently labeled Cy™ 3 labeled glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Invitrogen™) and serum free media
were added to tube two and left to incubate at RT for 5 min. The
two tubes were then mixed together and incubated for 10 min.
This mixture was then added directly to the plate and left for
24 h. Medium was then removed, replenished with fresh media
with and without LPS 100 ng/ml and left for another four hours.




STX3 #1 CAGCCUUCAUGGACGAGUUtt AACUCGUCCAUGAAGGCUGtg
STX3 #2 GGAAGAUGAGGUUCGGUCAtt UGACCGAACCUCAUCUUCCtc
Table 1 | Primers used for PCR and their sequences.
Gene Ref Seq ID Forward [5′–3′] Reverse [5′–3′]
SNAP-23 NM_009222 GTTCTTGCTCAGGCTTCC CCAACCAACCAATACCAATAATG
STX-2 NM_007941 GGTGGCAAAGGTGATGTT CAGGTATGGTCGGAGTCA
STX-3 NM_001025307 CCACAACCACTAGCATCATAA CTCAAGAGATATTCCGCCTTAA
STX-4 NM_009294 GGTGTCAAGTGTGAGAGAG AACCTCATCTTCATCGTCTG
STX-5 NM_001167799.1 GCAAGTCCCTCTTTGATGAT TTCAGATTCTCAGTCCTCACT
STX-6 NM_021433 CAAGGATTGTTTCAGAGATGGA CCTGACAATTTGCCGAGTA
STX-7 NM_016797 CACAACGCATCTCCTCTAAC TAATCGGTCTTTCTGTATCTTTCTC
STX-11 NM_001163591.1 ATCACGGCAAAATGAAGGA GGTCGGTCTCGAACACTA
STX-12 NM_133887 CGCAAGAAGATGTGTATCCT CTCTGAGGCAAGCACTTC
STX-16 NM_001102432.1 GAGCAGTACCAGAAGAAGAAC CAAGTCCTATCACCAATAATCCA
Vti1a NM_016862 GAATGTATAGCAACAGGATGAGA CCGTGTTATCCAGCAGATG
Vti1b NM_016862 TACCTTGGAGAACGAGCAT TGGACATTGAGCGAAGAATC
VAMP-1 NM_001080557 CCCTCTGTTTGCTTTCTCA CGTTGTCTTCGGGTAGTG
VAMP-2 NM_009497 CTCCTTCCCTTGGATTTAACC TGAAACAGACAGCGTATGC
VAMP-3 NM_009498 TTGTTCTTGTTGTATATCACTCCTAA GGCTCGCTCTCACAGTAT
VAMP-4 NM_016796 GTATGCCTCCCAAGTTCAAG TGTAGTTCATCCAGCCTCTC
VAMP-7 NM_011515 GATGGAGACTCAAGCACAAG GACACAATGATATAGATGAACACAAT
VAMP-8 NM_016794 GGCGAAGTTCTGCTTTGA CTTGACTCCCTCCACCTC
S18 NM_011296 CTGAGAAGTTCCAGCACATT GCTTTCCTCAACACCACAT
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Supernatants were removed and analyzed for the levels of IL-1β,
IL-6, TNF-α, and MIP-1α. Western blot was performed to verify
STX3 knockdown.
CONFOCAL MICROSCOPY
0.13–0.16 mm thick coverslips were placed in a six-well plate.
BMDCs harvested from C57BL/6 mice and JAWS II DCs were
added and left over-night to adhere. Cells were then stimulated
with LPS (100 ng/ml), Loxoribine (1 mM), and PGN (5µg/ml)
for 1 h. Cells were washed and fixed with 3% Paraformaldehyde
(PAF) and this reaction was then quenched with 50 mM Ammo-
nium Chloride. Cells were permeabilized with 0.1% saponin,
0.25% fish gelatin and 0.02% sodium azide in PBS. STX3
primary antibody was added to the coverslips and incubated
overnight at 4°C. Corresponding fluorescently conjugated sec-
ondary antibody (AlexaFluro 488 or AlexaFluro 546) was then
added to the coverslips and incubated for 1 h at room temperature.
Nuclei were stained with propidium iodide dye (PI) and samples
mounted using DAKO anti-fade medium. Slides were then viewed
using a Zeiss 710 confocal microscope and analyzed using LSM
software.
STATISTICS
The parametric student’s t -test was used using Excel (Microsoft) to
determine significant differences between two samples. The level
of statistical significance was indicated by *p≤ 0.05, **p≤ 0.01,
***p≤ 0.001.
RESULTS
SNARE mRNA EXPRESSION IN DCs FOLLOWING ACTIVATION WITH A
PANEL OF TLR LIGANDS
Using RT-quantitative polymerase chain reaction (qPCR) we ana-
lyzed the expression of Qa SNAREs (STX2, STX3, STX4, STX5,
STX7, STX11, STX12, and STX16) (Figure 1), Qb SNARES (Vti1a
and Vti1b), Qbc SNARE (SNAP23), Qc SNARE (STX6)(Figure 2),
and R SNAREs (VAMP1, VAMP2, VAMP3, VAMP4, VAMP7, and
VAMP8)(Figure 3) in JAWS II DCs following stimulation with
100 ng/ml LPS, 1 mM Loxoribine, or 5µg/ml PGN. RT-qPCR was
normalized with S18 levels. This housekeeping gene showed small-
est standard deviation compared to β-actin and GAPDH between
the technical replicates and LPS, Loxoribine and PGN stimula-
tion. Thus was used for all subsequent experiments (Figure S1 in
Supplementary Material).
The most significant fold change increases in mRNA expres-
sion in the Qa SNAREs over time were that of STX3 and STX11
(Figure 1). Expression of STX3 mRNA in JAWS II DCs sig-
nificantly increased following activation with LPS and Loxorib-
ine post 1 and 4 h stimulation and conversely was significantly
down-regulated following PGN activation (p≤ 0.01 and p≤ 0.05).
STX11 mRNA expression in JAWS II DCs increased significantly
following activation with LPS, Loxoribine and PGN at 1 and 4 h
compared to control cells (p≤ 0.001) (Figure 1).
In the assessment of expression of Qb SNARES (Vti1a and
Vti1b), Qbc SNARE (SNAP23), and Qc SNARE (STX6) there was
a significant up-regulation of Vti1a mRNA at 4 and 12 h post
LPS and Loxoribine stimulation (p≤ 0.01, p≤ 0.001, p≤ 0.01) in
comparison to control cells (Figure 2).
FIGURE 1 | Effect ofTLR ligand stimulation on Qa SNAREs (STX2,
STX3, STX4, STX5, STX7, STX11, STX12, and STX16) mRNA expression
in JAWS II DCs. JAWS II DCs were plated 1× 106/ml and stimulated with
100 ng/ml LPS, 1 mM Loxoribine, or 5µg/ml PGN at 1, 4, and 12 h. The
amount of specific SNARE protein was quantified by reverse transcription
followed by RT-qPCR and normalized with S18 levels. Fold differences were
calculated relative to SNARE levels at time zero (assigned value of 1).
Results are mean±SEM of quadruplicate assays. A two sample, two-tailed
student’s t -test comparing ∆Cts of control and 1, 4, or 12 h stimulated
sample *p≤0.05, **p≤0.01, ***p≤0.001
While VAMP1 was significantly down-regulated following
stimulation with LPS, Loxoribine, and PGN; VAMP2 was sig-
nificantly increased at 12 h post stimulation with these ligands
(Figure 3). Following Loxoribine stimulation VAMP8 expres-
sion was significantly down-regulated at 12 h (p≤ 0.05) and
up-regulated following PGN stimulation after 4 h. LPS stimu-
lation did not have any significant effect on VAMP8 expression
(Figure 3).
Our data demonstrate that SNAREs are regulated in JAWS II
DCs in response to TLR ligation and that their expression dif-
fered depending on the type of TLR ligand used to activate the cell
(Figures 1–3).
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FIGURE 2 | Effect ofTLR ligand stimulation on Qb SNARES (Vti1a and
Vti1b), Qbc SNARE (SNAP23), Qc SNARE (STX6) mRNA expression in
JAWS II DCs. JAWS II DCs were plated 1×106/ml and stimulated with
100 ng/ml LPS, 1 mM Loxoribine, or 5µg/ml PGN at 1, 4, and 12 h. The
amount of specific SNARE protein was quantified by reverse transcription
followed by RT-qPCR and normalized with S18 levels. Fold differences were
calculated relative to SNARE levels at time zero (assigned value of 1).
Results are mean±SEM of quadruplicate assays. A two sample, two tailed
student’s t -test comparing ∆Cts of control and 1, 4, or 12 h stimulated
sample *p≤0.05, **p≤0.01, ***p≤0.001.
SECRETION OF CYTOKINES AND CHEMOKINES BY DCs FOLLOWING
ACTIVATION WITH A PANEL OF TLR LIGANDS
To identify patterns in cytokine and chemokine secretion that may
correlate with the expression of SNAREs, we analyzed the secre-
tion of IL-6, TNF-α, and MIP-1α over the same time-course of 1, 4,
and 12 h (Figure 4). IL-6 secretion was significantly up-regulated
from JAWS II DCs following LPS stimulation at 4 h and 12 h and
Loxoribine at 12 h (p≤ 0.01, p≤ 0.001) but remained unchanged
following PGN stimulation. TNF-α secretion was significantly
up-regulated at 4 and 12 h following LPS, Loxoribine, and PGN
stimulation (p≤ 0.001, p≤ 0.05 and p≤ 0.01) and MIP-1α secre-
tion was significantly up-regulated following LPS stimulation at
FIGURE 3 | Effect ofTLR ligand stimulation on R SNAREs (VAMP1,
VAMP2,VAMP3,VAMP4,VAMP7, and VAMP8) mRNA expression in
JAWS II DCs. JAWS II DCs were plated 1×106/ml and stimulated with
100 ng/ml LPS, 1 mM Loxoribine, or 5µg/ml PGN at 1, 4, and 12 h. The
amount of specific SNARE protein was quantified by reverse transcription
followed by RT-qPCR and normalized with S18 levels. Fold differences were
calculated relative to SNARE levels at time zero (assigned value of 1).
Results are mean±SEM of quadruplicate assays. A two sample, two tailed
student’s t -test comparing ∆Cts of control and 1, 4, or 12 h stimulated
sample *p≤0.05, **p≤0.01, ***p≤0.001.
4 and 12 h (p≤ 0.01 and p≤ 0.001) and Loxoribine stimulation
at 12 h (p≤ 0.001) but not with PGN stimulation (Figure 4). The
trend of expression of IL-6 and TNF-α in response to LPS and
Loxoribine stimulation at 4 and 12 h and MIP-1 α at 4 h post
correlated with up-regulation of STX3 mRNA expression at 1 h fol-
lowing LPS and Loxoribine stimulation but not PGN stimulation
(Figures 1 and 4).
KNOCKDOWN OF STX3 SIGNIFICANTLY DECREASES THE SECRETION OF
IL-6 AND MIP-1 ALPHA FROM JAWS II DCs
As previous studies have indicated a role for STX3 in secretion
of chemokines (12) and we have demonstrated that increased
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FIGURE 4 |Time-course of cytokine and chemokine secretion from
JAWS II DCs in response toTLR4,TLR7, andTLR2 activation. JAWS II
DCs were cultured in r-GM-CSF for 7 days and subsequently were plated
(1×106 cells/ml) and left to rest overnight. Cells were then stimulated with
100 ng/ml LPS, 1 mM Loxoribine, and 5µg/ml PGN. Supernatants were
recovered after 1, 4, and 12 h and assessed for levels of cytokines using
specific immunoassays. Results are ±SEM of quadruplicate assays and
represent three independent experiments. *p≤0.05, **p≤0.01, and
***p≤0.001 comparing control versus stimulated JAWS II DCs as
determined by a two-tailed t -test.
expression of STX3 correlated with cytokine and chemokine secre-
tion we examined whether abolishing STX3 expression would
have any effect on cytokine or chemokine secretion from DCs.
STX3 was knocked down using STX3 specific siRNAs (Invitro-
gen™). Transfection efficiency was confirmed with Cy3 GAPDH
(Figure S2 in Supplementary Material) and STX3 knockdown by
both siRNAs was confirmed at the protein level by using Western
blot (Figure 5). Supernatants were subsequently removed 4 h later
and analyzed for basal levels of IL-1β, IL-6, TNF-α, and MIP-1α
(Figure 5). In the absence of STX3, secretion of IL-6 and MIP-1α
were significantly decreased (p≤ 0.05 and p≤ 0.01) whereas IL-1β
was significantly increased (p≤ 0.05), with no significant changes
in TNF-α secretion (Figure 5).
STX3 TRANSLOCATES TO THE PLASMAMEMBRANE ONLY IN IL-6
SECRETING JAWS II DCs AND BMDCs
We next used primary BMDCs to confirm our findings from the
JAWS II DC line. We analyzed secretion of IL-6, TNF-α, and
MIP-1α from BMDCs activated with LPS, Loxoribine, and PGN
and demonstrated that IL-6 is significantly secreted from BMDCs
when activated with all three TLR ligands (Figure 6A). mRNA
of STX3 was then examined in BMDCs and was up-regulated in
all instances where TLR activation of BMDCs resulted in IL-6
secretion, which supports our findings in the JAWS II cell line
(Figure 6B).
Given that we had shown correlation between secretion of IL-
6 and increased expression of STX3 in both JAWS II DCs and
BMDCs we next wanted to confirm this relationship by examining
the expression of STX3 in IL-6-secreting and non-secreting DCs
using confocal microscopy. STX3 was detected in the cytoplasm of
control JAWS II DCs and following stimulation with LPS and Lox-
oribine STX3 translocated to the plasma membrane after 1 h. PGN
stimulation in JAWS II DCs did not result in translocation of STX3
to the plasma membrane. In BMDCs, which do respond to PGN
and secrete IL-6, activation with PGN resulted in STX3 translo-
cation (Figure 7). Unstained cells and cells stained with primary
STX3 antibody (1°) alone were visualized for auto-fluorescence
while secondary antibodies alone were imaged for non-specific
binding in every experiment (Figure S3 in Supplementary Mater-
ial). An overview of our finding on STX3 in BMDCs and JAWS II
DCs are summarized in Figure 8.
DISCUSSION
Several studies have addressed the role of SNAREs in cytokine
release from immune cells, however, little is still known about the
specific SNAREs involved in cytokine or chemokine secretion by
DCs. Indeed, expression of SNAREs in immune cells, especially at
the mRNA level has also not been well characterized. Investigating
their expression in immune cells, such as DCs may provide valu-
able insights into their involvement in cytokine and/or chemokine
secretion thereby uncovering potential new targets in inflamma-
tory disease. Previous studies have used the correlation between
SNARE expression and cytokine secretion as a way of elucidat-
ing candidate SNAREs involved in the secretion of these immune
mediators (13). We took a similar approach and used the JAWS II
DC cell line to profile the expression of SNAREs and subsequent
secretion of cytokines and chemokines in DCs following expo-
sure to ligands for TLR2, TLR4, and TLR7. We demonstrate that
activation of DCs with these TLR ligands results in differential
expression of SNAREs and subsequent secretion of cytokines and
chemokines and describe a role for STX3 in secretion of IL-6.
Here, we have shown for the first time, the expression of SNARE
proteins in DCs following activation with a range of TLR ligands.
Interestingly, many of the SNAREs we examined did not change
in expression over the 12-h time points we assessed. This was of
interest as some SNAREs have been well reported to play a role
in other immune cells. For example, an up-regulation of STX6
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FIGURE 5 | Knockdown of STX3 by siRNA. JAWS II DCs were transfected
with siRNAs against STX3 (STX3 #1 and STX3 #2) or a negative control
non-silencing siRNA. At 24 h after the transfection, new media was put on the
cells and left for 4 h. Lysates and media were then harvested. Basal levels of
cytokines or chemokines were assessed using specific immunoassays and
knockdown was confirmed at protein level by western blot. *p<0.05 and
**p<0.01 comparing control versus STX3 siRNA transfected JAWS II DCs as
determined by a two-tailed t -test.
mRNA 2 h post stimulation with LPS has been reported in RAW
264.7 macrophage cells (3) and SNAP23 mRNA from the skeletal
muscle of patients with type II diabetes was up-regulated (14). As
SNAREs are used up during the fusion reactions and are recycled
for numerous rounds of transport (15), we propose that along with
caspases, other post-transcriptional regulation and recycling of
SNAREs may be another reason for the lack of changes of SNARE
mRNA expression in DCs.
We also did not detect any change in expression of VAMP8,
which is one of the only SNAREs, which has been assigned a
functionality in DCs to date. It has been previously indicated to
be involved in phagocytosis in DC. Ho et al. reported that an
over-expression of VAMP8 significantly inhibited phagocytosis
suggesting that VAMP8 negatively regulates this process (11).
The same group in another study notes that although they have
indicated a role for VAMP8 in DCs, VAMP8 mRNA was not signif-
icantly elevated during DC maturation (16). This correlates with
our data and Ho et al. accredited this to regulation at the mRNA
level of VAMP8 by caspases (16). This may be indicative for a role
for caspases and other molecules involved in post-transcriptional
regulation of SNARE mRNA in DCs as VAMP8 mRNA has been
shown to be up-regulated in other cells types such as over-reactive
human platelets. Indeed hyper-reactive platelets have a higher fold
expression of 4.8 compared to hypo-reactive platelets (17).
Our data does demonstrate significant up-regulation of
SNAREs such as STX3, STX11, Vti1a, and Vti1b in DCs follow-
ing activation. There was a significant up-regulation of Vti1a
mRNA at 4 and 12 h post LPS and Loxoribine stimulation. It has
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FIGURE 6 | (A) Cytokine and chemokine secretion from BMDC versus
JAWS II DCs in response to TLR2, TLR4, and TLR7. (B) Effect of TLR ligand
stimulation on Qa SNARE, STX3 mRNA expression in BMDCs. DCs were
cultured in r-GM-CSF for 7 days and subsequently were plated (1×106
cells/ml) and left to rest overnight. Cells were then stimulated with
100 ng/ml LPS, 1 mM Loxoribine, and 5µg/ml PGN and mRNA and
supernatants were recovered after 1 or 24 h Supernatants were assessed
for levels of cytokines using specific immunoassays and the amount of
STX3 was quantified by reverse transcription followed by RT-qPCR and
normalized with S18 levels. Fold differences were calculated relative to
SNARE levels at time zero (assigned value of 1). Results are ±SEM of
quadruplicate assays and represent three independent experiments.
*p≤0.05, **p≤0.01, and ***p≤0.001 comparing control versus
stimulated JAWS II DCs or BMDCs as determined by a two-tailed t -test.
previously been reported that up-regulation of Vti1a and Vti1b
inhibits phagocytosis in DCs (10). As mature DCs are known to
have reduced phagocytic ability (18) it may suggest that Vti1a was
up-regulated to inhibit phagocytosis as the DC matured. There
was also significant up-regulation of STX11 mRNA expression
in response to LPS Loxoribine and PGN compared to control
cells. STX11 is highly expressed in cells of the immune system
and interestingly has an already established role in immune dis-
ease. Loss or mutation of the STX11 gene results in an autosomal
recessive disorder known as, familial hemophagocytic lymphohis-
tiocytosis type-4 (FHL-4), which causes immune dysregulation.
This disorder is characterized by high levels of inflammatory
cytokines and defective function of T cells and natural killer (NK)
cells (19). STX11 has been reported to be up-regulated in DCs fol-
lowing LPS activation but Stx11 deficiency did not appear to affect
DC function (20). STX11 has also been indicated to regulate other
cells of the immune system such as NK, CD8+ T cells, macrophage,
platelets, and in human blood neutrophils where up-regulation of
STX11 mRNA expression during differentiation has been reported
(19–21). While it is clear from our study that STX11 regulation in
DCs may be important we did not find a definitive correlation
for this SNARE with the profile of cytokines or chemokines being
secreted by the DCs.
One of most significant increases in mRNA expression over
time was that of STX3. Expression of STX3 mRNA in JAWS II DCs
significantly increased following activation with LPS and Loxorib-
ine 1 and 4 h post stimulation and conversely was down-regulated
following PGN activation. A role for STX3 has been documented
in mast cells and epithelial cells but not yet in DCs. STX3 and
VAMP7 have been shown to be important for apical transport
of trans-membrane and secretory proteins in epithelial cells (22).
Interestingly, a role for STX3 has been recently documented in the
secretion of chemokines from mast cells. This study demonstrated
that blocking STX3 activity with neutralizing antibodies inhib-
ited the secretion of chemokines following IgE stimulation. The
chemokines inhibited included IL-8, MCP-1, MIP-1α, and MIP-
1β (12). As the JAWS II DCs secreted large amounts of MIP-1α it
suggested that STX3 also has a role in chemokine secretion in DCs.
To elucidate a role for these up-regulated SNAREs we assessed
the secretion of IL-6, TNF-α, and MIP-1α from JAWS II DCs
following activation with TLR4, TLR7, and TLR2 ligands over
the same time-course that the SNARE mRNA was profiled. IL-
6 and MIP-1α were significantly secreted when JAWS II DCs were
stimulated with LPS and Loxoribine but not with PGN. This
was of particular interest to us as STX3 expression in JAWS II
DCs was up-regulated significantly in response to LPS and Lox-
oribine but not to PGN stimulation. The concept of SNARE
up-regulation paralleled with cytokine up-regulation has proven
useful in other studies. Murray et al. correlated SNARE pro-
tein levels with TNF secretion from macrophage following LPS
stimulation, which ultimately lead to the elucidation of STX4 func-
tionality in macrophage secretion of TNF-α(3). The different roles
of each SNARE in different immune cells is highlighted by the fact
that in contrast to the role of STX4 in macrophage, we demon-
strate a key role for this SNARE in secretion of IgE in B cells (23).
With these factors in mind we examined STX3 in further detail to
elucidate its functional roles in DCs.
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FIGURE 7 | Localization of STX3 to the plasma membrane in JAWS II DCs
and BMDCs. JAWS II DCs and BMDCs were plated 1×106/ml and
stimulated with 5µg/ml PGN, 100 ng/ml LPS, and 1 mM Loxoribine for 1 h.
Immunofluorescent indirect double staining of STX3 (Green) and nuclei (red)
in TLR4, TLR7, and TLR2 stimulated JAWS II DCs and BMDCs to show
localization of STX3 within the cells.
FIGURE 8 | Overview of findings. Schematic representation of
secretion of cytokines and chemokines secreted from JAWS II DCs and
BMDCs in response to TLR activation. mRNA expression up-regulation
and translocation of STX3 in DCs only secreting IL-6 (red) while MIP-1α
(blue) was also secreted in these cells, not to the same level as in
BMDCs
We firstly depleted the levels of STX3 by means of a siRNA spe-
cific to STX3. In these experiments, IL-6 secretion was significantly
down-regulated in the absence of STX3. MIP-1α was also down-
regulated when STX3 was depleted by using RNAi. This correlates
with recent data from mast cells where STX3 was reported to be
involved in chemokine release from mast cells (12). Using confocal
microscopy we assessed the cellular location of STX3 during acti-
vation with TLR ligands in both JAWS II DCs and BMDCs, and
showed that translocation of STX3 only occurred in cells where
IL-6 was secreted. This data indicates that STX3 has a role in IL-6
secretion (and possibly MIP-1α) from DCs and is an important
SNARE in DC function.
IL-6 levels were not completely abolished from the JAWS II
DCs and this may be explained as loss of SNAREs can be com-
pensated by other members of the SNARE family, which have only
30% amino acid similarity (24). However, cytokines such as IL-
6 are critical mediators of the autoimmune diseases and IL-6 is
implicated in several disease processes. Increased levels of IL-6
have been observed in IBD, RA, systemic-onset juvenile chronic
arthritis (JCA), osteoporosis, and psoriasis (25). IL-6 blockade has
also been reported to be successful in autoimmune diseases and
humanized anti-IL-6 receptor antibody is now routinely used in
the clinic for the treatment of RA and JCA (26). In the past decade,
IL-6 has been implicated with TGF-β in the differentiation of the
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Th17 subset, therefore its blockade may potentially improve these
diseases at the pathogenic initiation phase (27).
The importance of future work in identifying SNARE com-
plexes in immune function is highlighted by the award of a Nobel
prize to Randy W. Schekman, Thomas C. Südhof and James E.
Rothman who identified and functionally characterized these pro-
teins and their involvement in trafficking. The potential to develop
therapeutics that target SNAREs and suppress the secretion of
cytokines may have significant advantages over therapies that tar-
get the effects of these cytokines post release. Indeed SNAREs may
represent novel therapeutic targets in a wide range of disease states.
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